Visceral Leishmaniasis among immunosuppressed patients with rheumatic diseases.
Erre
G L
GL
Mesina
P
P
Tonelli
N
N
Passiu
G
G
D000068879:Adalimumab; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000188:drug therapy; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D007898:Leishmaniasis, Visceral / Q000175:diagnosis* / Q000453:epidemiology*; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D009894:Opportunistic Infections / Q000175:diagnosis* / Q000453:epidemiology*; D015995:Prevalence; D012307:Risk Factors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D000068879:Adalimumab; D008727:Methotrexate